The QWINT-3 study compared efsitora with daily shots of Novo Nordisk’s NVO Tresiba (insulin degludec) for 78 weeks in T2D patients who have switched from daily basal insulin injections.

Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Novo Nordisk will lower the US list prices for Tresiba and Fiasp by more than 70% starting January 1, 2026, following the lowering of its other insulin products on January 1, 2024. The company ...

Its portfolio includes insulin analogs, GLP-1 receptor agonists, and oral antidiabetic drugs like Rybelsus, Ozempic, and Tresiba. Novo Nordisk A/S (NYSE:NVO) delivered exceptional financial ...